Opicapone Oral Capsule [Ongentys]
RxNorm 2362175

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2362175 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: opicapone Oral Capsule [Ongentys].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDF
Opicapone Oral Capsule [Ongentys]
AUI:12389430
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDFPrescribable

Semantic Branded Drug Form (SBDF):
Opicapone Oral Capsule [Ongentys]
(Atom ID: 12389430)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
opicapone Oral Capsule [Ongentys]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2362175
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12389430
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDF
Semantic Branded Drug Form (Ingredient + Dose Form + Brand Name)
Source Code
2362175
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Opicapone


Opicapone is used along with levodopa and carbidopa (Sinemet, Rytary) to treat the end-of-dose 'wearing-off' symptoms of Parkinson's disease. Opicapone is an inhibitor of catechol-O-methyltransferase (COMT). Opicapone helps the levodopa and carbidopa work better by allowing more of it to reach the brain, where it has its effects.
[Learn More]


* Please review the disclaimer below.